Form 4: NextCure Director Anne Elizabeth Borgman Acquires Stock Options
SEC Form 4 Filing
Director Anne Elizabeth Borgman acquired stock options in NextCure, Inc. on June 20, 2024.
Summary
- Anne Elizabeth Borgman, a director of NextCure, Inc., reported a transaction involving derivative securities.
- On June 20, 2024, Borgman acquired 18,700 stock options with an exercise price of $1.50.
- These options vest fully on the earlier of June 20, 2025, and the date of the 2025 Annual Meeting of Stockholders.
- The options expire on June 19, 2034.
- Following the transaction, Borgman directly owns 18,700 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, common for publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction: Acquisition of stock options. |
| 06/20/2025 | Options vest in full on the earlier of this date and the date of the 2025 Annual Meeting of Stockholders. |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.